Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV004799558 | SCV001468750 | uncertain significance | Dilated cardiomyopathy 1G; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2019-07-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002480931 | SCV002776651 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2021-09-13 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004538563 | SCV004121391 | uncertain significance | TTN-related disorder | 2023-05-25 | criteria provided, single submitter | clinical testing | The TTN c.36196G>A variant is predicted to result in the amino acid substitution p.Asp12066Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.087% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-179529387-C-T). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |